<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553810</url>
  </required_header>
  <id_info>
    <org_study_id>2018/2182</org_study_id>
    <nct_id>NCT03553810</nct_id>
  </id_info>
  <brief_title>Role of ARNi in Ventricular Remodeling in Hypertensive LVH</brief_title>
  <acronym>REVERSE-LVH</acronym>
  <official_title>Role of ARNi in Ventricular Remodeling in Hypertensive LVH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart Centre Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart Centre Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Singapore, hypertension is very common in the adult population. Hypertensive heart disease
      is a leading cause of heart failure and cardiovascular death. Current management relies
      primarily on achieving blood pressure targets. However, the optimal blood pressure goals are
      controversial and there are inherent difficulties in measuring blood pressure using external
      devices applied to peripheral arteries. As a result of (usually longstanding) hypertension,
      the heart thickens (i.e. hypertrophies) to maintain function. Ultimately, HF may occur due to
      long standing energy deficits, muscle injury/death and diffuse interstitial fibrosis (heart
      muscle scarring). In an ongoing study (REMODEL, ClinicalTrial.gov Identifier NCT02670031), we
      have been able to undertake preliminary analyses with respect to factors associated with the
      development of fibrosis. In this randomize controlled trial, we will be examining a novel
      therapy that has the potential to induce regression cardiac hypertrophy and fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrosis volume</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in fibrosis volume measured on CMR. Extracellular volume fraction (ECV) will be quantified from native and post-contrast myocardial T1. Fibrosis volume is defined as ECV x myocardial volume and indexed to body surface area (ml/m2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass measured on CMR</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in left ventricular mass, indexed to body surface area (g/m2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker/biochemistry</measure>
    <time_frame>52 weeks</time_frame>
    <description>Identify potential markers as indicators of cardiac structural effects of ARNi and ARB</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypertensive Heart Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entresto (valsartan/sacubitril) 100mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan 40mg once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entresto</intervention_name>
    <description>Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Valsartan/sacubitril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.</description>
    <arm_group_label>Controlled Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Increased left ventricular mass on cardiovascular magnetic resonance (based on
             established local age- and sex-specific CMR ranges)

          -  Essential hypertension

        Exclusion Criteria:

          -  Known secondary causes of hypertension

          -  Previous intolerance to angiotensin receptor blockers

          -  History of heart failure

          -  Stage IV/V chronic renal disease (eGFR &lt; 30ml/min/1.73m2)

          -  Patients with serum potassium &gt; 5.2 mmol/L (mEg/L) at Visit 1

          -  History of cardiovascular events (myocardial infarction, strokes and transient
             ischemic attacks)

          -  Known atrial fibrillation

          -  Being unable to understand or comply with study procedures (including CMR)

          -  History or presence of any other disease with a life expectancy of &lt; 3 years

          -  Pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <last_name>Calvin WL Chin, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Calvin WL Chin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

